drugset / Trial / NCT04588077

Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis

NCT04588077

Phase 4 Recruiting 200 enrolled Mercy Medical Center
RandomizedParallel-groupOpen-labelPrevention

Summary

Investigators want to compare the seroconversion rates between two-dose and three-dose regimens of the hepatitis B vaccine (Heplisav B) among patients with cirrhosis, a randomized prospective study.

Timeline

Start
2020-09-14
Primary completion
2028-12-01
Completion
2028-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject HEPLISAV-B Vaccine